Madras High Court restrains Patanjali from using trademark 'Coronil'

Justice Karthikeyan passed the order valid till July 30 on the plea of Chennai-based company Arudra Engineering Private Limited

Patanjali
To substantiate its claim, the petitioner produced sales bills of the products for the past five years.
Press Trust of India Chennai
2 min read Last Updated : Jul 17 2020 | 11:48 PM IST
The controversial drug of yoga guru Ramdev's Patanjali Ayurved Ltd - Coronil- which is claimed as a cure for Covid-19, has received a blow with the Madras High Court restraining the company from using the trademark 'Coronil'.

Justice C V Karthikeyan passed the interim order valid till July 30 on the plea of Chennai-based company Arudra Engineering Private Limited which has claimed that 'Coronil' is a trademark owned by it since 1993.

According to the company which is into manufacturing chemicals and sanitisers to clean heavy machineries and containment units, it has registere 'Coronil-213 SPL' and 'Coronil-92B' in 1993 and has been diligently renewing the trademark since then.

"Currently, our right over the trademark is valid till 2027," the company said.

Claiming that its products with the trademark have a global presence, the company claimed that its clients include BHEL and Indian Oil.

To substantiate its claim, the petitioner produced sales bills of the products for the past five years.
"The mark adopted by Patanjali for its drugs are clearly identical to the marks registered by the company. Though the products sold by the company are different, use of identical trademarks would still amount to infringement of our intellectual property right, the company said.

"Permitting Patanjali to continue to use the mark will directly affect our reputation and the goodwill created over the mark for over 26 years in both international and domestic markets," the petitioner added.

After Patanjali launched Cornonil, the Union AYUSH Ministry had, on July 1, said the company can sell the drug only as an immunity booster and not as a cure for Covid-19.

Ramdev had reacted to the criticism on the efficacy of Coronil, saying some people were hurt by the rise of indigenous medicine.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusMadras HCPatanjali Ayurved

Next Story